Summary: Serum and urinary neopterin concentrations were measured in 142 patients suffering from various inalignant diseases. Increased serum and urinary neopterin levels were found in 48% and 55% of patients respectively. Neopterin showed sufficient sensitivity in the detection of haematological disorders and hypernephroma, whereas the sensitivity of neopterin was rather poor in patients with other solid tumours.
Neopterin als Tiunormarker: Neopterinkonzentrationen in Serum und Harn bei malignen Erkrankungen

Introduction
Pterines are required äs cofactors for the hydroxylation of various Substrates (1) , and the excretion of pterines seems to be associated with cell proliferation. Recently it has been demonstrated that macrophages stimulated with factors (i. e. interferon gamma) from activated T-lymphocytes release large amounts of neopterin (2) . Therefore, neopterin is believed to represent a potential marker for biochemical monitoring of diseases caused by or associated with T-lymphocyte activation. Increased urinary neopterin levels have been reported in patients suffering from viral infections (3), autoimmune disorders (4), in patients with acquired immunodeficiency syndrome (5) and in allograft rejection (6) . Kokolis & Ziegler demonstrated increased pterine concentrations in the blood of cancer patients (7) , and enhanced urinary excretion of pterines was found in mice bearing Ehrlich ascites tumours (8) . Elevated urinary neopterin levels were also reported in various malignant tumours (9, 10) and haematological diseases (11) .
In the present study serum and urinary neopterin levels were measured in patients suffering from various malignant diseases. Serum and urinary neopterin levels were determined before and after chemotherapy to evaluate the role of neopterin in monitorî ng cancer patients. The clinical significance of the well established tumour markers -fetoprotein (AFP) and human chorionic gonadotrqpin (HCG) was compared to neopterin in testicular cancer patients. Serum and urinary neopterin concentrations were also determined in patients with nonmalignant diseases without any evidence for an inflammätory prö-cess and in patients with inflammätory diseases.
In addition, the determination of neopterin excretion in urine specimens by radioimmünological methods (RIA) and high performance liquid chromatography (HPLC) was compared.
Patients and Methods
Neopterin in serum and urine Blood was taken in the fasting state, protected from light, and serum samples were stored at -20°C until analysed. Results are reported in nmol/1 neopterin. Neopterin conceatrations in serum were determined by a commercially available radiöinv munoassay kit (neopterh>RIAcid/serum, Henning, BerlinWest, FRG), which employs a double antibody techniqüe with preprecipitated antiserum and [ 125 I]neopterin äs tracer. Samples and antiserum were incubated at room temperature for l hour, then the tracer solution was added and incubated at foom temperature for a furtber hour. Bound and non-bound tracer were separated by addition of pölyethyleüe glycöl solution (60 J. Clin. Chem. Clin. Biochem. / Vol. 24, 1986 / No. 2 g/l) and centrifugation. Radioactivity of the precipitate was measured in a gammacounter. Concentrations were calculated by Standards from 0 to 160 nmol/1. Urinary neopterin concentrations were measured in the first specimcn of daily urine. Urine samples were collected, protected from light, and stored al -20 °C. Neopterin and creatinine determinations in the specimens were performed by HPLC on reversed phase, using an automated System device (Neopterin System, Varian International A. G., Zug, Switzerland). Urine samples were diluted l : 6 with 15 mmol/1 potassium phosphate buffer (pH 7.0). Diluted sample (10 μΐ) was injected onto the column and neopterin was quantitated after Chromatographie Separation by its native fluorescence (353 nm excitation, 438 nm emission wavelength). Simultaneously, urinary creatinine was measured using the UV-absorbance at 235 nm. Neopterin results are reported in μπιοΐ/mol creatinine.
In addition, urinary neopterin concentrations were measured using a commerciaUy available RIA-kit (neopterin-RIA/urine, Henning, Berlin-West, FRG). Urine samples were determined by the same method s described for the neopterin-RIA/serum after oxidation with I 2 for half an hour in the dark.
AFP and HCG concentrations in serum AFP concentrations in serum were determined using an enzyme-immunoassay (AFP-EIA Diagnostik Kit, Abbott Laboratories, North Chicago, U. S. A.).
HCG (HCG + HCG ) levels in serum were measured radioimmunologically (HCG-RIA, Serono, Milano, Italy).
Patients
Serum and urinary neopterin levels were measured in 38 normal controls (male and female subjects aged 18-72 years with no evidence of cancer or any other disease).
142 previously untreated patients suffering from vario s malignant diseases were examined. In all cases malignancy was histologically verified: 31 patients with disseminated testicular cancer (8 seminoma and 23 nonseminomatous germ cell turnours), 15 patients with multiple myeloma, 8 patients with prostatic cancer, 11 patients with bladder tumours, 15 hypernephroma patients, 28 patients suflering from malignant haematological disorders (7 acute myelocytic leukaemia, 2 chronic myelocytic leukaemia, 19 lymphonaa patients) and a gro p of 34 patients suffering from vario s other tumours (12 gastrpintestinal cancer, 3 melanoma, 11 lung cancer, 6 sarcoma and 2 other carcinoma patients). In addition, serum and urinary neopterin levels were measured in the following groups: 16 patients after successful removal of the primary testicular t mour and radical retroperitoneal lymphadenectomy and no evidence of metastases in a careful clinical staging; 28 patients with vario s diseases (cardiovascular diseases, chronic heart failure, emphysema, prostatic hypertrophy, fertility disorders), but no evidence for an inflammatory process; and 23 patients with inflammatory diseases (8 pneumonia, 4 acute bronchitis, 5 pyelonephritis, '3 prostatitis and 3 epididymitis patients). Statistical analysis was performed using Studenfs tatest.
Results
Imprecision
The imprecision (day per day) for the determination of neopterin in serum (RIA) was CV = 8%, in urine (HPLC) CV = 3%, and in urine (RIA) CV = 9% respectively.
Neopterin in controls
In healthy controls mean neopterin levels in serum were 5.3 ± 1.7 (SD) nmol/1. Mean urinary neopterin levels s determined by HPLC were 139 ± 40 μπιοί/ mol creatinine. The upper limit of the normal r nge (x + 2 SD) was taken s 8.7 nmol/1 in serum and 220 μτηοΐ/mol creatinine in urine samples.
Neopterin in malignant diseases
48% of patients with malignant diseases showed elevated neopterin concentrations in serum, and 55% of patients showed an increased urinary neopterin excretion (flg. 1). Particularly in cases of malignant haematological disorders (leukaemia and lymphoma patients) most patients showed pathological levels of neopterin in serum (65%) and urine (91%). In hypernephroma patients elevated serum and urinary neopterin levels were found in 71 % and 89% of cases, respectively ( fig. 1 of chemotherapy and serum or urinary neopterin levels was found in patients with malignant diseases imdergoing chemotherapy. In testicular cancer patients receiving adjuvant chemotherapy, pretherapeutic serum and urinary neopterin concentrations were normal in 93% and 92% of cases, respectively. After chemotherapy, 50% of patients showed elevated serum neopterin levels, and 58% showed increased urinary excretion rates; neopterin concentrations in serum increased from 5.8 + 2.2 to 12.0 ± 7.6 nmol/1 (p < 0.005), and urinary neopterin excretion increased from 98 ± 34 to 274 ± 133 μιηοΐ/ mol creatinine (p < 0.0005; flg. 2).
AFP, HCG and neopterin in testicular cancer
Serum AFP, HCG and serum and urinary neopterin levels were conipared in testicular tumour patients (tab. 1). In metastasized seminoma, 3 patients showed elevated HCG levels in serum, and all patients had normal AFP values. Determination of serum or urinary neopterin concentrations gave no additional Information in this patient group.
In nonseminomatous germ cell tumours, the sensitivity of serum or urinary neopterin was about 50% compared to serum AFP or HCG. Combination of AFP and HCG indicated the presence of metastatic disease in 19 out of 23 patients. In the "adjuvant" testicular tumour patients, known to be tumour free, no false positive AFP or HCG values were observed, whereas l patient showed false positive seram and 3 patients showed increased urinary neopterin excretion rates.
Neopterin in nonmalignant diseases
Elevated neopterin levels in serum were measured in 24% of patients suffering from various diseases b t showing no evidence for an inflammatory process, and 37% of these patients showed increased urinary neopterin excretion rates. Pathological serum and urinary neopterin levels were ineasured in patients with inflammatory diseases in 55% and 59% respectively ( fig. 3 ).
-1000 .g Comparison of neopterin in urine determined by RIA or HPLC
Comparison of the determination of urinary neopterin concentrations using RIA or HPLC showed a good correlation between both methods ( fig. 4) , the coefficient of correlation was 0.785. However, RIA gave somewhat higher results particularly in urine samples with high neopterin concentrations.
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Discussion
Elevated urinary neopterin excretion rates were reported in a wide variety of malignant diseases, and determination of neopterin is suggested äs a useful biochemical marker in monitoring cancer patients (9, 10, 11) . Neopterin is believed to be produced by cells involved in the host's immune defense against the tumour, but not by the tuinour cells (2, 12) . In haematological neoplasias the total frequency of elevated urinary neopterin levels was reported to be about 85% (11) . In the present study, the sensitivity of neopterin äs a tumour marker in serum and urine was found to be sufficient in haematological malignancies (leükaemia and lymphoma) and in 'hypernephroma patients. In our stüdy, the sensitivity of neopterin was rather poor in metastasized testicular cancer patients, in prostate and bladder cancer, äs well äs in various other solid tumours, all patients being in an advanced stage of the disease, mpst of them with extensive metastasis.
In the testicular tumour group, consisting of patients after orchiectomy and radical retroperitoneal lymphadenectomy, known to be tumour free, l patient showed elevated serum and 3 patients increased urinary neopterin levels. An increase in urinary neopterin excretion rates was reported in patients who had undergone surgery between the third and the sixth day after laparotomy (13) . However, in these patients neopterin determinations were performed 4 weeks after lymphadenectomy, and in only l patient could the increased urinary excretion rates be explained by an infection in the lymphadenectomy scar.
"False positive" neopterin concentrations were also reported in various non-malignant diseases (3, 9) including rheumatoid arthritis (4), tuberculosis (14) äs well äs during menstruation (15) . In accordance with these findings we found increased serum and urinary neopterin levels in patients with various nonmalignant diseases. In patients with inflammatory processes "false positive" serum and urinary neopterin values were observed in 55% and 59% of patients respectively. Serum neopterin levels rise with increasing serum creatinine concentrations (16) , but in the group of patients with non-malignant diseases with and without inflammatory processes all patients had a normal renal function, so that elevated neopterin levels could not be explained by renal diseases or renal insufficiency. The sensitivity of neopterin äs a tumour marker is poor in solid tumours, and "false positive" values frequently occur with various diseases and viral infections, including trivial illnesses, such äs the common cold (15) . This reflects the poor specificity of the marker. Determination of serum or urinary neopterin is of no value for initial screening for cancer patients.
Comparison of neopterin with the well-established tumour markers, AFP and HCG, in testicular cancer, showed that, in accordance with the poor sensitivity, determination of neopterin provides no further Information in the diagnostic procedure of testicular cancer patients. Again, false positive neopterin values were measured in the tumour-free testicular tumour group, whereas all patients showed normal AFP or negative HCG values in this group.
In contrast to the findings of Sichler et al. (17) , who reported a good correlation between radiotherapy and chemotherapy and urinary neopterin excretion in cancer patients, we found no correlation between the^ success of chemotherapy and serum or urinary neopterin levels. When testicular tumour patients, known to be tumour free, received adjuvant chemotherapy, a significant increase in serum and urinary neopterin values after chemotherapy was found. Elevated neopterin concentrations were found in the serum of 50% of patients, and in the urine of 58% of patients. Therefore, determination of neopterin is Leukocytes of no value in monitoring the course and effect of chemotherapy in these patients, since neopterin values arise significantly after chemotherapy. Daily determination of serum and urinary neopterin concentrations before, during and after chemotherapy, showed that the decrease in blood leukocyte count was accompanied by an increase in neopterin levels; this indicates tHat neopterin is released from macrophages during the cell damage caused by chemotherapy ( fig. 5 ).
However, in haematological disorders and in hypernephroma patients the sufficient sensitivity indicates that determination of neopterin might be of some value in monitoring these patients.
Determination of urinary neopterin concentratipiis with a RIA-method compared to HPLC showed a good correlation, but the results obtained with the RIA were higher, particularly when high neopterin concentrations were present in the urine sample, indicating that non-oxidized pterines (i. e. 7,8* dihydroneopterin) were also measured with the RIAmethod. However, the RIA for neopterin represents an attractive alternative if the HPLC-equipment is not available in the laboratory.
